Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XT 150

Next Previous
Drug Profile

XT 150

Alternative Names: IL-10 transgene plasmid DNA; XT 101; XT-101-R; XT-150

Latest Information Update: 12 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xalud Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Eye disorder therapies; Gene therapies; Non-opioid analgesics; Skin disorder therapies
  • Mechanism of Action Gene transference; Interleukin 10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Musculoskeletal pain
  • Preclinical Amyotrophic lateral sclerosis; Eye disorders; Gastrointestinal disorders; Multiple sclerosis; Skin disorders
  • Research Unspecified
  • No development reported Neuropathic pain

Most Recent Events

  • 29 Nov 2024 Xalud Therapeutics plans a phase I trial for Amyotrophic Lateral Sclerosis in USA in February 2025 (Intrathecal, Injection) (NCT06704347)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Neuropathic-pain in Australia (Intrathecal, Injection)
  • 10 Nov 2023 Efficacy data from the phase II trial in Pain presented at the ACR Convergence 2023 (ACR-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top